Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Heart Attack Warning Sign Discovered

By HospiMedica International staff writers
Posted on 19 Jan 2011
A new study has found that elevated blood levels of the cleaved p17 fragment of the caspase-3 peptide (p17)--the end effector caspase for apoptosis--can serve as a predictor of acute myocardial infarct (AMI).

Researchers at the University of Connecticut (Storrs, USA) studied 27 consecutive patients undergoing primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) with a door-to-balloon time of less than 90 minutes, between December 2007 and January 2010. More...
The researchers measured p17 levels at least twice 8 hours apart during the initial 24 hours, and the peak level was determined as the higher of the AMI values. Cardiac troponin I (cTnI) and creatine kinase (CK) levels were determined every 8 hours for 24 to 36 hours, with the 99th percentile value as the upper limit.

The researchers found that peak serum p17 peptide level during AMI was higher than the late post-MI serum level in 21 subjects in whom samples were available during both phases. Compared with healthy subjects, the peak AMI p17 level was nearly 4-fold higher than that in healthy subjects; the late post-MI p17 peptide level was also higher than that of healthy subjects, consistent with persistent apoptosis after AMI. In all subjects, the peak p17 peptide level occurred after PCI and was positively correlated with the peak cTnI and and peak CK levels. The researchers suggest that rise and fall of p17 peptide and its correlation with peak cTnI and CK suggest that serum p17 likely came from injured myocardium. The study was published in the January 11, 2011, issue of the Journal of the American College of Cardiology.

"We've discovered a new biomarker for heart attack, and showed that apoptosis, or a particular kind of cell death, is a cause of heart muscle damage,” said lead author Bruce Liang. "The ability to see a heart attack coming with a simple blood test and to develop new therapies to block apoptosis would enable us to get a head start on treatment and preserve crucial heart muscle and cardiac function.”

Related Links:

University of Connecticut



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.